<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537780</url>
  </required_header>
  <id_info>
    <org_study_id>Montelukast</org_study_id>
    <nct_id>NCT04537780</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Montelukast in Non Alcoholic Steatohepatitis (NASH)</brief_title>
  <official_title>Clinical Study Evaluating the Efficacy and Safety of Montelukast in the Treatment of Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the current study is to evaluate the efficacy and safety of Montelukast in the treatment of&#xD;
      patients with non-alcoholic steatohepatitis (NASH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, prospective placebo-controlled study that will be conducted on 44&#xD;
      patients who fulfill the selection criteria and will be classified randomly into two groups.&#xD;
&#xD;
      Group 1 (Control group n= 22): Patients will receive Placebo once daily at bedtime.&#xD;
&#xD;
      Group 2 (Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.&#xD;
&#xD;
      The treatment duration will be 12 weeks. Patients will be recruited from National Liver&#xD;
      Institute and Fever, Liver and GIT disease Shebin El-Kom hospital, Egypt. All participants&#xD;
      will be informed about the nature of the study. The patients will give their informed&#xD;
      consent.The study will be approved by Research Ethics Committee of faculty of pharmacy -Tanta&#xD;
      University. Data of all patients will be private and confidential. Any unexpected risk will&#xD;
      be reported to patients and ethical committee on time&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Actual">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">August 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, prospective placebo controlled study that will be conducted on 44 patients who fulfill the selection criteria and will be classified randomly into two groups.&#xD;
Group 1 (Control group n= 22): Patients will receive Placebo once daily at bedtime.&#xD;
Group 2 (Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime. The treatment duration will be 12 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum 8-Hydroxy2-deoxyguanisine (8-OHdG)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Quantitative detection of human 8-OHdG will be done using commercially available Enzyme-linked Immunosorbent assay kits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF-α.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Quantitative detection of TNF-α will be done using commercially available Enzyme-linked Immunosorbent assay kits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alanine aminotransferase (ALT).</measure>
    <time_frame>12 Weeks</time_frame>
    <description>ALT will be measured by colorimetric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aspartate aminotransferase (AST)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>AST will be measured by colorimetric method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ɤ-glutamyltranspeptidase(GGT)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>ɤ-glutamyltranspeptidase(GGT) will be measured by colorimetric method.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Non Alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>(Control group n= 22): Patients will receive Placebo once daily at bedtime for 12 weeks..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment group n= 22): Patients will receive Montelukast 10 mg daily at bedtime.&#xD;
The treatment duration will be 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tabled every day</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
    <description>Montelukast 10 mg daily at bed time.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Singulair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (&gt;18 years) overweight/obese subjects who have persistently abnormal&#xD;
             aminotransferase level in two separate occasions over the past six months.&#xD;
&#xD;
        NAFLD will be assumed in patients with moderately elevated aminotransferase activities (&lt;3x&#xD;
        the upper limit of normal).&#xD;
&#xD;
        There is evidence of hepatic steatosis by imaging (increased liver echogenicity (bright),&#xD;
        stronger echoes in the hepatic parenchyma, vessel blurring, and narrowing of the lumen of&#xD;
        the hepatic veins) and there is no cause for secondary hepatic fat accumulation such as&#xD;
        significant alcohol consumption, use of steatogenic medication or hereditary disorders.&#xD;
        Patients with fibroscan score &gt;7 kPa and &lt;14 kPa will be included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol abusers.&#xD;
&#xD;
          -  Presence of evidence for viral or autoimmune hepatitis.&#xD;
&#xD;
          -  Diabetic patients.&#xD;
&#xD;
          -  Patients with Wilson's disease and patients with hemochromatosis.&#xD;
&#xD;
          -  Patients with decompensated liver disease.&#xD;
&#xD;
          -  Patients show hypersensitivity to studied medications.&#xD;
&#xD;
          -  Patients taking medication known to cause steatosis.&#xD;
&#xD;
          -  Patients with other comorbid conditions that could potentially elevate transaminase,&#xD;
             such as congestive heart failure, malignancy.&#xD;
&#xD;
          -  Pregnancy and lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarek M Mostafa, Ass. Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Tarek Mohamed Mostafa</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Said MM, Bosland MC. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate. Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):197-205. doi: 10.1007/s00210-016-1325-4. Epub 2016 Dec 1.</citation>
    <PMID>27909742</PMID>
  </reference>
  <reference>
    <citation>Kuru S, Kismet K, Barlas AM, Tuncal S, Celepli P, Surer H, Ogus E, Ertas E. The Effect of Montelukast on Liver Damage in an Experimental Obstructive Jaundice Model. Viszeralmedizin. 2015 Apr;31(2):131-8. doi: 10.1159/000375434. Epub 2015 Apr 9.</citation>
    <PMID>26989383</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>August 30, 2020</last_update_submitted>
  <last_update_submitted_qc>August 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Dr. Tarek Mohamed Mostafa</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

